Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, ahead of expected biosimilar market formation in 2023.
So far, only a limited number of developers have pursued Humira biosimilars with a higher-strength 100mg/ml formulation, with most preferring...






